Silo Pharma, Inc. (SILO)
- Previous Close
1.9600 - Open
1.9600 - Bid --
- Ask --
- Day's Range
1.9529 - 2.0300 - 52 Week Range
1.2160 - 3.0500 - Volume
12,739 - Avg. Volume
134,519 - Market Cap (intraday)
5.716M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
silopharma.comRecent News: SILO
Performance Overview: SILO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SILO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SILO
Valuation Measures
Market Cap
5.60M
Enterprise Value
-2.06M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
84.15
Price/Book (mrq)
0.91
Enterprise Value/Revenue
-28.62
Enterprise Value/EBITDA
0.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.86%
Return on Equity (ttm)
-43.97%
Revenue (ttm)
72.1k
Net Income Avi to Common (ttm)
-3.63M
Diluted EPS (ttm)
-1.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
7.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.78M
Research Analysis: SILO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell